As Bristol Myers Squibb (BMY) Share Value Declined, Nelson Roberts Investment Advisors Increased Its Stake by $4.64 Million; Homrich & Berg Maintains Stake in Cvs Health (CVS)

November 24, 2017 - By Nellie Frank

Homrich & Berg increased its stake in Cvs Health Corp (CVS) by 203.39% based on its latest 2017Q2 regulatory filing with the SEC. Homrich & Berg bought 6,726 shares as the company’s stock declined 4.23% while stock markets rallied. The institutional investor held 10,033 shares of the medical and nursing services company at the end of 2017Q2, valued at $807,000, up from 3,307 at the end of the previous reported quarter. Homrich & Berg who had been investing in Cvs Health Corp for a number of months, seems to be bullish on the $72.39 billion market cap company. The stock decreased 0.03% or $0.02 on November 22, reaching $71.48. About shares traded. CVS Health Corp (NYSE:CVS) has declined 24.40% since November 24, 2016 and is downtrending. It has underperformed by 41.10% the S&P500.

Nelson Roberts Investment Advisors Llc increased its stake in Bristol Myers Squibb (BMY) by 3514.17% based on its latest 2017Q2 regulatory filing with the SEC. Nelson Roberts Investment Advisors Llc bought 84,340 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 86,740 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $4.83 million, up from 2,400 at the end of the previous reported quarter. Nelson Roberts Investment Advisors Llc who had been investing in Bristol Myers Squibb for a number of months, seems to be bullish on the $99.90 billion market cap company. The stock decreased 0.16% or $0.1 on November 22, reaching $61.14. About shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 24, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.




Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It fall, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Everence Cap Management Incorporated holds 0.47% or 34,674 shares in its portfolio. Washington Tru holds 0.06% or 17,755 shares in its portfolio. Private Cap Inc has invested 0.13% in Bristol-Myers Squibb Co (NYSE:BMY). Wealth Enhancement Advisory Ser Limited Liability has 0.11% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 20,715 shares. Mairs And Pwr reported 343,043 shares. Moreover, Bp Public Ltd Com has 0.39% invested in Bristol-Myers Squibb Co (NYSE:BMY). Axa accumulated 397,431 shares. Kbc Grp Inc Nv has invested 0.23% in Bristol-Myers Squibb Co (NYSE:BMY). Keating Counselors Incorporated reported 0.73% in Bristol-Myers Squibb Co (NYSE:BMY). Connecticut-based Verition Fund Management Limited Liability Company has invested 0.04% in Bristol-Myers Squibb Co (NYSE:BMY). Bnp Paribas Asset Mgmt Holdings Sa accumulated 711,821 shares or 0.35% of the stock. Jacobus Wealth Mgmt Incorporated has invested 0.56% in Bristol-Myers Squibb Co (NYSE:BMY). Sector Gamma As reported 7.2% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Optimum Inv Advsr invested in 1.1% or 57,119 shares. Piedmont Advsr Limited Liability stated it has 434,496 shares or 0.54% of all its holdings.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.53’s average target is 2.27% above currents $61.14 stock price. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, October 6 by UBS. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Underweight” rating given on Monday, August 24 by Piper Jaffray. The company was maintained on Monday, July 10 by Cowen & Co. The firm earned “Underperform” rating on Friday, July 28 by BMO Capital Markets. Atlantic Securities initiated Bristol-Myers Squibb Co (NYSE:BMY) rating on Friday, December 18. Atlantic Securities has “Underweight” rating and $57 target. The firm earned “Hold” rating on Thursday, October 19 by Cowen & Co. Jefferies maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Tuesday, March 15. Jefferies has “Hold” rating and $65 target. The firm has “Buy” rating by Guggenheim given on Wednesday, December 2. The firm has “Equal-Weight” rating given on Friday, October 13 by Barclays Capital. The company was downgraded on Tuesday, September 12 by Hilliard Lyons.

More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Squibb (BMY) Presents at Jefferies 2017 London Healthcare …” on November 15, 2017, also Nasdaq.com with their article: “Bristol-Myers Squibb Co. Reports 8% Decline In Q3 Bottom Line” published on October 26, 2017, Gurufocus.com published: “First Quadrant LP Buys Boeing Co, Vanguard REIT, Bristol-Myers Squibb Company …” on October 25, 2017. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: Investorplace.com and their article: “Industry Group Rank Limit Bristol-Myers Squibb Co (BMY) Rating” published on November 17, 2017 as well as Economictimes.Indiatimes.com‘s news article titled: “Biocon arm widens partnership terms with Bristol-Myers Squibb” with publication date: November 14, 2017.

Among 24 analysts covering CVS Health (NYSE:CVS), 15 have Buy rating, 0 Sell and 9 Hold. Therefore 63% are positive. CVS Health had 53 analyst reports since July 22, 2015 according to SRatingsIntel. As per Monday, August 10, the company rating was maintained by Argus Research. The stock of CVS Health Corp (NYSE:CVS) has “Buy” rating given on Thursday, June 23 by Mizuho. The stock of CVS Health Corp (NYSE:CVS) has “Neutral” rating given on Friday, November 3 by Citigroup. On Friday, August 28 the stock rating was maintained by Oppenheimer with “Outperform”. Cowen & Co maintained the stock with “Buy” rating in Tuesday, June 13 report. Jefferies downgraded the shares of CVS in report on Monday, December 12 to “Hold” rating. As per Wednesday, August 5, the company rating was maintained by RBC Capital Markets. The firm earned “Hold” rating on Tuesday, November 7 by Jefferies. The stock of CVS Health Corp (NYSE:CVS) earned “Buy” rating by Oppenheimer on Tuesday, August 8. Jefferies maintained it with “Hold” rating and $82.0 target in Wednesday, August 16 report.

More notable recent CVS Health Corp (NYSE:CVS) news were published by: Seekingalpha.com which released: “CVS: Undervalued” on November 16, 2017, also Courant.com with their article: “Report: Buyout Of Aetna Inc. Could Come This Month” published on November 20, 2017, Reuters.com published: “CVS bid for Aetna: A $66 billion bet on cutting drug costs” on October 29, 2017. More interesting news about CVS Health Corp (NYSE:CVS) were released by: Cnbc.com and their article: “‘Insane’: Wall Street analysts puzzled by CVS Health’s possible costly foray …” published on October 27, 2017 as well as Fool.com‘s news article titled: “Better Buy: CVS Health Corporation vs. Wal-Mart” with publication date: November 16, 2017.

Homrich & Berg, which manages about $3.37B and $1.14 billion US Long portfolio, decreased its stake in Coca Cola Co (NYSE:KO) by 10,001 shares to 221,408 shares, valued at $9.93M in 2017Q2, according to the filing. It also reduced its holding in Schwab Strategic Tr (SCHF) by 11,715 shares in the quarter, leaving it with 75,024 shares, and cut its stake in Jpmorgan Chase & Co (AMJ).

Since June 12, 2017, it had 0 insider purchases, and 1 insider sale for $18.44 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.